Biohaven Ltd. Reports Partial Clinical Hold on BHV-7000; SKBP License

What Happened

• Biohaven reported that the U.S. Food and Drug Administration issued a partial clinical hold on September 4, 2026 that pauses new patient enrollment in its BHV-7000 program while additional nonclinical studies are completed to characterize a specific metabolite observed in rodent testing. The partial hold applies to new enrollment only; dosing continues for patients already randomized (more than 600 across the program).
• BHV7000-303 (one of two pivotal refractory focal epilepsy trials) was fully enrolled as of June 2026, dosing continues, and topline data remain on track for the second half of 2026. BHV7000-302 will continue dosing for already randomized patients but has paused new enrollment pending the additional nonclinical data expected in the coming weeks. Biohaven has dosed over 1,200 participants across the BHV-7000 development program to date.
• Separately, on August 26, 2026 Biohaven’s wholly owned subsidiary (BBIL) signed a License Agreement with SK Biopharmaceuticals Co., Ltd. granting SKBP an exclusive, royalty-bearing, worldwide license to Biohaven’s Kv7 ion channel platform, including BHV-7000. All clinical and nonclinical data were disclosed to SKBP before signing; closing requires completion of the Hart-Scott-Rodino (HSR) filing.

Key Details

• FDA partial clinical hold date: September 4, 2026; applies to new patient enrollment only.
• Dosing continues for >600 patients already randomized; >1,200 participants have been dosed across the program historically.
• BHV7000-303 fully enrolled (June 2026) with topline readout expected in H2 2026; BHV7000-302 enrollment paused for new patients.
• License Agreement signed Aug 26, 2026 with SK Biopharmaceuticals for global rights to the Kv7 platform; HSR submission pending.

Why It Matters

• The FDA partial hold introduces a near-term operational risk to expanding enrollment in U.S. sites and could delay enrollment-dependent activities for BHV7000-302 until the nonclinical metabolite data are clear. However, because the hold permits continued dosing of already randomized patients and BHV7000-303 is fully enrolled, the company expects no immediate impact to the BHV7000-303 topline timing.
• The licensing deal with SK Biopharma transfers worldwide commercial rights to the Kv7 platform (including BHV-7000) and could provide Biohaven with partner resources and future financial upside, subject to closing and regulatory clearance (HSR). The metabolite findings are currently of uncertain human relevance and additional studies are expected to clarify safety implications in the coming weeks.